Gut Dysbiosis and Increased Intestinal Permeability Drive microRNAs, NLRP-3 Inflammasome and Liver Fibrosis in a Nutritional Model of Non-Alcoholic Steatohepatitis in Adult Male Sprague Dawley Rats.
fatty liver disease models
fibrosis
gut microbiota
non-alcoholic fatty liver disease
non-alcoholic steatohepatitis
Journal
Clinical and experimental gastroenterology
ISSN: 1178-7023
Titre abrégé: Clin Exp Gastroenterol
Pays: New Zealand
ID NLM: 101532800
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
05
2020
accepted:
23
07
2020
entrez:
28
9
2020
pubmed:
29
9
2020
medline:
29
9
2020
Statut:
epublish
Résumé
The interactions between the gut and liver have been described in the progression of non-alcoholic steatohepatitis (NASH). The aim of this study was to develop an experimental nutritional model of NASH simulating metabolic changes occurring in humans. Adult male Sprague Dawley rats were randomized into two groups: controls (standard diet) and intervention (high-fat and choline-deficient diet) for 16 weeks, each experimental group with 10 animals. Biochemical analysis, hepatic lipid content, microRNAs, inflammatory, gut permeability markers and gut microbiota were measured. Animals in the intervention group showed significantly higher delta Lee index ( This experimental model mimicking human NASH demonstrated gut and liver interaction, with gut microbiota and intestinal permeability changes occurring in parallel with systemic and liver inflammation, miRNAs regulation and liver tissue damage.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The interactions between the gut and liver have been described in the progression of non-alcoholic steatohepatitis (NASH). The aim of this study was to develop an experimental nutritional model of NASH simulating metabolic changes occurring in humans.
MATERIALS AND METHODS
METHODS
Adult male Sprague Dawley rats were randomized into two groups: controls (standard diet) and intervention (high-fat and choline-deficient diet) for 16 weeks, each experimental group with 10 animals. Biochemical analysis, hepatic lipid content, microRNAs, inflammatory, gut permeability markers and gut microbiota were measured.
RESULTS
RESULTS
Animals in the intervention group showed significantly higher delta Lee index (
CONCLUSION
CONCLUSIONS
This experimental model mimicking human NASH demonstrated gut and liver interaction, with gut microbiota and intestinal permeability changes occurring in parallel with systemic and liver inflammation, miRNAs regulation and liver tissue damage.
Identifiants
pubmed: 32982365
doi: 10.2147/CEG.S262879
pii: 262879
pmc: PMC7509481
doi:
Types de publication
Journal Article
Langues
eng
Pagination
351-368Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Longo et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Biomed Res Int. 2015;2015:574832
pubmed: 26064924
Gastroenterology. 2014 May;146(6):1513-24
pubmed: 24440671
Nutrients. 2019 Dec 16;11(12):
pubmed: 31888190
Eur J Gastroenterol Hepatol. 2008 Jun;20(6):519-25
pubmed: 18467911
World J Gastroenterol. 2016 Aug 28;22(32):7353-64
pubmed: 27621581
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
Transplantation. 2019 Jan;103(1):e1-e13
pubmed: 30300287
J Hepatol. 2018 May;68(5):1063-1075
pubmed: 29408694
Cells. 2019 Oct 27;8(11):
pubmed: 31717860
J Obes. 2012;2012:319172
pubmed: 22778916
World J Gastroenterol. 2012 May 21;18(19):2300-8
pubmed: 22654421
J Gastroenterol Hepatol. 2007 Sep;22(9):1526-33
pubmed: 17716355
GE Port J Gastroenterol. 2016 Mar 31;23(3):132-141
pubmed: 28868449
Appl Environ Microbiol. 2009 Dec;75(23):7537-41
pubmed: 19801464
J Hepatol. 2018 Aug;69(2):385-395
pubmed: 29572095
Chem Biol Interact. 2007 Jan 30;165(2):106-16
pubmed: 17188672
Nutr Metab Cardiovasc Dis. 2018 Apr;28(4):369-384
pubmed: 29482963
Mol Med. 2017 May;23:70-82
pubmed: 28332698
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
BMC Gastroenterol. 2014 Nov 18;14:189
pubmed: 25407511
Gastroenterol Clin North Am. 2017 Mar;46(1):155-169
pubmed: 28164848
J Hepatol. 2008 Dec;49(6):1055-61
pubmed: 18929425
Pharmaceuticals (Basel). 2018 Oct 11;11(4):
pubmed: 30314377
J Nutr Biochem. 2014 Jan;25(1):81-90
pubmed: 24314869
Gastroenterology. 1998 Apr;114(4):842-5
pubmed: 9547102
Nat Immunol. 2011 May;12(5):408-15
pubmed: 21478880
Nutrients. 2019 Sep 09;11(9):
pubmed: 31505802
Metabolism. 2017 Apr;69:177-187
pubmed: 28285648
Nutrients. 2017 Sep 27;9(10):
pubmed: 28953222
World J Gastroenterol. 2016 Feb 28;22(8):2533-44
pubmed: 26937141
Br J Nutr. 2016 Jul;116(2):191-203
pubmed: 27197843
Mol Cell Biol. 2014 Mar;34(6):1100-20
pubmed: 24421392
Metabolism. 2016 Aug;65(8):1038-48
pubmed: 26823198
Int J Exp Pathol. 2017 Aug;98(4):221-233
pubmed: 28895242
Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25
pubmed: 27273168
Gastroenterology. 2015 Mar;148(3):547-55
pubmed: 25461851
Nucleic Acids Res. 2013 Jan;41(Database issue):D590-6
pubmed: 23193283
Cell Mol Life Sci. 2019 Apr;76(8):1541-1558
pubmed: 30683985
Hepatol Int. 2018 Jan;12(1):6-16
pubmed: 29299759
PLoS One. 2014 Dec 23;9(12):e115922
pubmed: 25535951
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
PeerJ. 2016 Oct 18;4:e2584
pubmed: 27781170
Nutrients. 2019 Jul 16;11(7):
pubmed: 31315227
Liver Int. 2018 Jun;38(6):1084-1094
pubmed: 29164820
J Gastroenterol Hepatol. 2020 Apr 8;:
pubmed: 32267559
BMC Gastroenterol. 2016 Jun 13;16(1):61
pubmed: 27296438
J Mol Med (Berl). 2014 Oct;92(10):1069-82
pubmed: 24861026
Br J Nutr. 2009 Apr;101(8):1178-84
pubmed: 19007450
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Diabetes. 2006 Jul;55(7):2015-20
pubmed: 16804070
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
PLoS One. 2015 May 27;10(5):e0127991
pubmed: 26017539
Int J Exp Pathol. 2013 Apr;94(2):93-103
pubmed: 23305254
Int J Mol Sci. 2016 Mar 25;17(4):447
pubmed: 27023533
J Pathol. 2017 Jan;241(1):36-44
pubmed: 27757953
J Hepatol. 2016 Sep;65(3):579-88
pubmed: 27261415
Dig Dis Sci. 2017 Feb;62(2):396-406
pubmed: 27913996
Gut. 2015 May;64(5):800-12
pubmed: 24973316
Gastroenterology. 2016 May;150(5):1147-1159.e5
pubmed: 26874076
Life Sci. 2020 Mar 15;245:117356
pubmed: 31991181
Nat Methods. 2010 May;7(5):335-6
pubmed: 20383131
J Gastroenterol Hepatol. 2015 Jul;30(7):1190-6
pubmed: 25684563
Sci Rep. 2017 Sep 22;7(1):12200
pubmed: 28939830
Hepatology. 2013 Feb;57(2):601-9
pubmed: 23055155
J Hepatol. 2019 Dec;71(6):1216-1228
pubmed: 31419514
Hepatology. 2016 Mar;63(3):764-75
pubmed: 26600078
Front Pharmacol. 2018 Jan 12;8:980
pubmed: 29375381